Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?
Department of Medical Oncology.
Barouyr
B
Baroudjian
Department of Medical Oncology,, INSERM U981.
Lise
L
Boussemart
Department of Medical Oncology.
Emilie
E
Routier
Dermatology Clinic, Hôtel Dieu, Nantes, FRANCE.
Brigitte
B
Dreno
Department of Radiation Oncology.
Yungan
Y
Tao
Department of Radiation Oncology.
Eric
E
Deutsch
Department of Radiation Oncology.
Pierre
P
Blanchard
Department of Radiation Oncology.
Frédéric
F
Dhermain
Department of Radiology, Institute Gustave Roussy, 114 rue Edouard Vaillant, 94800 Villejuif, FRANCE.
Laurence
L
Vilcot
INSERM U981.
Stephan
S
Vagner
Department of Medical Oncology.
Alexander
A
Eggermont
Department of Medical Oncology.
Christine
C
Mateus
Department of Medical Oncology,, INSERM U981.
Caroline
C
Robert
D000328:Adult; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000532:radiotherapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
D007211:Indoles; D011838:Radiation-Sensitizing Agents; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf